Chester County News and Community Website
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) recently granted equity inducement awards to 24 newly hired employees on April 14, 2026, under its 2021 Inducement Equity Incentive Plan.
Savara Grants Equity Awards to 24 New Employees Read More LANGHORNE, PA — The U.S. Food and Drug Administration has extended the review period for Savara Inc.’s (Nasdaq: SVRA) biologics license application for molgramostim by three months, setting a new …
FDA Extends Review of Savara’s Molgramostim Application to November Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) will present new clinical data on its investigational therapy molgramostim at the ATS International Conference in Orlando, Florida, May 17–20, 2026, the company …
Savara to Present Molgramostim Data at ATS 2026 Conference Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said the U.K.’s Medicines and Healthcare products Regulatory Agency recently accepted its marketing authorization application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis, …
Savara Says UK Regulator Accepts MOLBREEVI Application Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said the European Medicines Agency has validated its marketing authorization application for MOLBREEVI, initiating a formal review of the treatment for autoimmune pulmonary …
Savara Advances MOLBREEVI Reviews in U.S., Europe, U.K. Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) reported fourth-quarter and full-year 2025 financial results while advancing its MOLBREEVI program, including a filed Biologics License Application with the U.S. Food and …
Savara Reports 2025 Results, Advances MOLBREEVI Toward Approval Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said the U.S. Food and Drug Administration does not plan to convene an advisory committee for its review of the MOLBREEVI biologics license …
Savara Says FDA Review of MOLBREEVI to Proceed Without Advisory Committee Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said the U.S. Food and Drug Administration has accepted for review its biologics license application for MOLBREEVI as a treatment for autoimmune pulmonary …
Savara’s MOLBREEVI BLA Receives FDA Priority Review Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) granted stock options and restricted stock units covering a total of 15,000 shares to a newly hired employee on February 10, 2026, the …
Savara Grants Inducement Equity Awards to New Employee Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it has amended its loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), unlocking significant non-dilutive financing tied to a pending …
Savara Secures Path to $150M as FDA Decision Nears for Rare Lung Drug Read More